A Molecular Subtype–Specific Stochastic Simulation Model of US Breast Cancer Incidence, Survival, and Mortality Trends from 1975 to 2010

Medical Decision Making

Volumn 38, Issue 1_suppl, 2018, Pages 89S-98S

  Munoz, Diego F ^a   Xu, Cong ^a   Plevritis, Sylvia K ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer incidence trends; breast cancer mortality trends; nonproportional hazards; SEER; time dependent treatment effects

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGED; BREAST TUMOR; CANCER REGISTRY; CANCER STAGING; COMPARATIVE STUDY; COMPUTER SIMULATION; DIAGNOSTIC IMAGING; FEMALE; HUMAN; MAMMOGRAPHY; MARKOV CHAIN; MIDDLE AGED; MONTE CARLO METHOD; MORTALITY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PROTO ONCOGENE; RISK ASSESSMENT; STATISTICAL MODEL; SURVIVAL; SURVIVAL ANALYSIS; TRENDS; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COMPUTER SIMULATION; FEMALE; GENES, ERBB-2; HUMANS; MAMMOGRAPHY; MIDDLE AGED; MODELS, STATISTICAL; MONTE CARLO METHOD; MORTALITY; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RISK ASSESSMENT; SEER PROGRAM; STOCHASTIC PROCESSES; SURVIVAL; SURVIVAL ANALYSIS; UNITED STATES; YOUNG ADULT;

EID: 85040538606     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X17737508     Document Type: Article

References (23)

1. Berry DA, Cronin KA, Plevritis SK. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784–92.
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–72.
3. Romond EH, Perez EA, Bryant J. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.
4. Slamon DJ, Eiermann W, Robert N. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–83.
5. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.
6. Dowsett M, Cuzick J, Ingle J. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509–18.
7. Yin W, Jiang Y, Shen Z, Shao Z, Lu J. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS One. 2011;6(6):e21030.
8. Slamon DJ, Leyland-Jones Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.
9. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.
10. Cox DR. Regression models and life-tables. J Royal Stat Soc. Series B (Methodol). 1972;34(2):187–220.
11. Jeong JH, Jung SH, Wieand S. A parametric model for long-term follow-up data from phase III breast cancer clinical trials. Stat Med. 2003;22(3):339–52.
12. Berry DA, Cirrincione C, Henderson IC. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295(14):1658–67.
13. Dignam JJ, Dukic VM, Anderson SJ, Mamounas EP, Wickerham DL, Wolmark N. Hazard of recurrence and adjuvant treatment effects over time in lymph node–negative breast cancer. Breast Cancer Res Treat. 2009;116(3):595–602.
14. Jatoi I, Bandos H, Jeong JH. Time-varying effects of breast cancer adjuvant systemic therapy. J Natl Cancer Inst. 2016;108(1):djv304.
15. Plevritis SK, Sigal BM, Salzman P, Rosenberg J, Glynn P. A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000. J Natl Cancer Inst Monogr. 2006;(36):86–95.
16. Mandelblatt JS, Near AM, Miglioretti DL. Common model inputs in collaborative breast cancer modeling. Medical Decis Making. 2018;38(1S):9–23.
17. Jackson H, Vanness D, Stout NK. Contribution of breast cancer to overall mortality for U.S. women. Medical Decis Making. 2018;38(1S):24–31.
18. Holford TR. The estimation of age, period and cohort effects for vital rates. Biometrics. 1983;39(2):311–24.
19. Holford TR, Cronin KA, Mariotto AB, Feuer EJ. Changing patterns in breast cancer incidence trends. J Natl Cancer Inst Monogr. 2006;(36):19–25.
20. Munoz DF, Plevritis SK. Understanding the temporal trends in breast cancer incidence in the United States: a novel approach to address identifiability in age-period-cohort models. Manuscript in preparation.
21. Munoz DF, Plevritis SK. Estimating breast cancer survival by molecular subtype in the absence of screening and treatment. Under review for publication.
22. Alagoz O, Berry D, de Koning H. Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) breast cancer models. Med Decis Making. 2018;38(1S):3–8.
23. Burstein HJ, Temin S, Anderson H. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255–2269.